Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty

Basit Öğe Kaydı
dc.contributor.authorKirkgoz T.
dc.contributor.authorKarakoc-Aydiner E.
dc.contributor.authorBugrul F.
dc.contributor.authorYavas Abali Z.
dc.contributor.authorHelvacioglu D.
dc.contributor.authorKiykim A.
dc.contributor.authorBilgic Eltan S.
dc.date.accessioned2020-03-26T20:20:51Z
dc.date.available2020-03-26T20:20:51Z
dc.date.issued2020
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Besides local reactions, systemic hypersensitivity reactions such as urticaria, anaphylaxis, serum sickness and Henoch-Schönlein purpura (HSP) have been reported during gonadotropin-releasing hormone (GnRH) analogue treatment. Aim: To present the clinical presentation of 9 cases with systemic hypersensitivity reactions to GnRH analogues and discuss the management of such reactions based on our experience. Patients and Methods: Nine of 232 (3.8%) patients with central precocious puberty receiving GnRH analogue treatment had systemic hypersensitivity reactions in 4 years' period. Six patients had a type 1 hypersensitivity reaction (generalized hives, pruritus, and/or edema) to triptorelin acetate (TA), 2 patients to leuprolide acetate (LA), and 1 patient to both medications who also developed anaphylaxis to LA during intradermal test (IDT). Another patient on TA had skin lesions suggestive of HSP. GnRH analogue treatment was discontinued in 2 patients after discussion with the parents. Treatment was changed to another GnRH analogue preparation in 6 patients and was maintained with the same medication with antihistamines and corticosteroid premedication in 1 patient. None of the patients developed new reactions after these precautions. Conclusion: Systemic hypersensitivity reactions should be carefully evaluated and cross-reaction to the other GnRH analogues should be kept in mind. Discontinuation of GnRH analogue is always an option. However, if continuation of GnRH analogue is elected, we recommend switching to an alternative GnRH analogue, which should be considered only after a skin prick test (SPT) and IDT. In the lack of the possibility to perform SPT and IDT, injections may be administered under strict medical supervision in a well-equipped facility to manage anaphylaxis. We discuss additional options in situations where alternative GnRH analogues are unavailable, which enabled us to continue treatment in most cases without further problems. © 2020 © 2020 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000505329en_US
dc.identifier.issn1663-2818en_US
dc.identifier.pmid31972562en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000505329
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38685
dc.identifier.wosWOS:000546456300008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherS. Karger AGen_US
dc.relation.ispartofHormone Research in Paediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdverse reactionsen_US
dc.subjectAnaphylaxisen_US
dc.subjectCentral precocious pubertyen_US
dc.subjectDrug-related side effectsen_US
dc.subjectGonadotropin-releasing hormone analoguesen_US
dc.titleManagement of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Pubertyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu